why choose us

First received: April 20, 2023

Clinical Trial: A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumors, Adult

Study Type: INTERVENTIONAL


Official Title: A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase ? Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in

Brief Summary: HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.

Read more